Aller au contenu

The European Hematology Association 26th congress EHA 2021

9 Juin 2021 · 9 joursOnline, Pays-BasHématologieAnglais
The European Hematology Association 26th congress EHA 2021
Online

À propos de ce congrès

EHA continues to dedicate its efforts to guiding hematologists in both clinical and research settings.
Although face-to-face interactions are an important aspect of any congress, the current pandemic severely limits the possibilities. A core objective of EHA is to provide a platform for networking and connecting hematologists and EHA2021 will be no different. We will strive to maximize opportunities to promote the social side of our congress for our participants.

The EHA2021 Virtual Congress will be a key moment to consolidate the knowledge and experience gained worldwide and bring together hematologists in a virtual environment

MEDFLIXS couvrira les temps forts de ce congrès sous forme d'interviews vidéo et de best-of disponibles pour les professionnels de santé inscrits.

Vidéos de ce congrès

Martin Hutchings · Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
Lancer la vidéo · Martin Hutchings · Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaInscription gratuite requise pour lancer la lecture

Martin Hutchings · 00:05:58

John Allan · CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
Lancer la vidéo · John Allan · CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLLInscription gratuite requise pour lancer la lecture

John Allan · 00:10:40

Bijal Shah · ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell
Lancer la vidéo · Bijal Shah · ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cellInscription gratuite requise pour lancer la lecture

Bijal Shah · 00:09:21

Othman Al-Sawaf · CLL14: Venetoclax plus obinutuzumab in untreated CLL
Lancer la vidéo · Othman Al-Sawaf · CLL14: Venetoclax plus obinutuzumab in untreated CLLInscription gratuite requise pour lancer la lecture

Othman Al-Sawaf · 00:05:11

Jorge Cortes · Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML
Lancer la vidéo · Jorge Cortes · Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CMLInscription gratuite requise pour lancer la lecture

Jorge Cortes · 00:07:01

Paola Ghione · A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control
Lancer la vidéo · Paola Ghione · A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external controlInscription gratuite requise pour lancer la lecture

Paola Ghione · 00:03:39

Claudio Cerchione · Carfilzomib-lenalidomide-dexamethasone in the management
Lancer la vidéo · Claudio Cerchione · Carfilzomib-lenalidomide-dexamethasone in the managementInscription gratuite requise pour lancer la lecture

Claudio Cerchione · 00:06:49

Nicholas Short · A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic
Lancer la vidéo · Nicholas Short · A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblasticInscription gratuite requise pour lancer la lecture

Nicholas Short · 00:05:51

Nicholas Short · Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia
Lancer la vidéo · Nicholas Short · Interim results of a phase II study of blinatumomab plus ponatinib for PhiladelphiaInscription gratuite requise pour lancer la lecture

Nicholas Short · 00:05:41

Arnon Kater · Fixed-duration ibrutinib and venetoclax for first-line CLL
Lancer la vidéo · Arnon Kater · Fixed-duration ibrutinib and venetoclax for first-line CLLInscription gratuite requise pour lancer la lecture

Arnon Kater · 00:07:35

Katja Weisel · Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatment
Lancer la vidéo · Katja Weisel · Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatmentInscription gratuite requise pour lancer la lecture

Katja Weisel · 00:03:50

Cristina Gasparetto · Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory
Lancer la vidéo · Cristina Gasparetto · Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractoryInscription gratuite requise pour lancer la lecture

Cristina Gasparetto · 00:07:48